Non-peptide comparator · published research references
Volixibat
Governed scientific comparator
4 approved source records with original-source links. Source verification confirms the reference and its connection to this record; it does not certify every scientific conclusion or establish safety or efficacy.
This reference comparator is not classified as a peptide.
Approved source records
A randomised, double-blind, placebo-controlled phase 1 study of the safety, tolerability and pharmacodynamics of volixibat in overweight and obese but otherwise healthy adults: implications for treatment of non-alcoholic steatohepatitis.
DOI: 10.1186/s40360-018-0200-y
Source identity and connection checked by Codex (AI).
Apical sodium-dependent bile acid transporter inhibition with volixibat improves metabolic aspects and components of non-alcoholic steatohepatitis in Ldlr-/-.Leiden mice.
DOI: 10.1371/journal.pone.0218459
Source identity and connection checked by Codex (AI).
Efficacy, Safety and Tolerability of Volixibat, an IBAT Inhibitor, in Patients With Intrahepatic Cholestasis of Pregnancy.
Source identity and connection checked by Codex (AI).
Volixibat in adults with non-alcoholic steatohepatitis: 24-week interim analysis from a randomized, phase II study.
DOI: 10.1016/j.jhep.2020.03.024
Source identity and connection checked by Codex (AI).
Legacy research context
Context from the legacy curated dataset. Its counts describe that dataset and are separate from the live approved source records above.
Researchers represented
- Ovadia C
- Stone S
- Sibai B
- Nunes T
- Mogul DB
- Krishnaswami J
- Kahng J
- Li F
- Warsi QA
- Chien E
- Vig P
- Williamson C
- Newsome PN
- Palmer M
- Freilich B
- Sheikh MY
- Sheikh A
- Sarles H
- Herring R
- Mantry P
- Kayali Z
- Hassanein T
- Lee HM
- Aithal GP
- Volixibat in Adults study group
- Jennings L
- Silberg DG
- Bliss C
- Martin P
- Salic K
- Kleemann R
- Wilkins-Port C
- McNulty J
- Verschuren L